Summary by Futu AI
MICROCHUN MEDICAL SCIENCE CO., LTD. (MICROCHUN MEDICAL) ANNOUNCED ITS 2023 ANNUAL RESULTS ANNOUNCEMENT PUBLISHED ON THE SCIENTIFIC BOARD OF THE SHANGHAI STOCK EXCHANGE SCIENTIFIC BOARD OF THE SHANGHAI STOCK EXCHANGE (MICRO CHUNG MEDICAL TECHNOLOGY) OF APPROXIMATELY 40.32%. Cardiac Medical Technologies achieved total operating revenue of approximately $11.87 billion in 2023, up 32.43% year-on-year; operating profit of approximately $5.74 billion, up 38.21%; total profit of approximately $5.72 billion, up 38.26%; net profit attributable to parent company owners was approximately $4.92 billion, up 37.98%, according to the Express. In addition, basic earnings per share were $6.81, an increase of 37.30% year-on-year, and the weighted average net asset yield increased 4.21 percentage points to 26.43%. At the end of the reporting period, the Company's total assets grew by 112.62%, reflecting a 94.56% increase in net...Show More